Call for Abstracts

Abstract submission portal is now closed.

The abstract submission portal is now closed. All submitting authors will be notified of their acceptance by March 30, 2019. 

The HHT International Scientific Conference is hosted and sponsored by Cure HHT. The Conference Organizing Committee invites authors to submit abstracts to be considered for inclusion in the Scientific Program for either oral or poster presentations. 

The conference sessions will be organized around the themes of Mechanism, Diagnosis, Treatment, Genetics, Drug Discovery, and Epidemiology, however, other topics of research are encouraged and welcomed for submission. Within each of these themes we will bring together basic scientists and clinicians, in the hope of stimulating and educating both.

Abstracts should only include original data. Case reports must be submitted for poster presentation. 

Submit Abstract


If you have any problems with the abstract submission process, please contact Nicole Schaefer at conference@curehht.org.

Abstract Guidelines

  • The abstract must be written in English.
  • The abstract should be organized as follows: Title; Authors; Affiliations; Objective; Method; Result; Conclusion.
  • The abstract title should be in capital letters.
  • Author names should be listed in the following order: last name, first initial, degree.
  • All authors should be listed and the presenting author’s name should be underlined.
  • Author affiliations should be listed in the following order: department, institution, city, state, and country.
  • The abstract text should be a maximum of 250 words (not including title, authors or affiliations).
  • Font 12 pt Arial, single-spaced, 1″ margins.
  • There is no limit to the number of abstracts a presenter can submit, but the Organizing Committee expects that all abstracts selected for presentation will be presented by the first author.
  • The submitter can choose their preference of presentation type – oral or poster – but the final decision will be up to the Organizing Committee.  Abstracts will be reviewed and scored based on actual results reported in the abstract; abstracts without any data will receive a lower score. Case reports will only be selected for poster presentations.
  • Abstracts should be submitted electronically by 11:59 pm EST on February 22, 2019.
  • All submitters will receive notification of abstract acceptance and presentation type by March 30, 2019.

Contact Person

Nicole Schaefer
Director, Professional & Medical Programs

Email: conference@curehht.org

Phone: 410-357-9932 (US)

Outstanding Oral Presentation and Poster Awards

Outstanding Oral Presentation and Poster Awards will be presented to Residents, Postdoctoral/Clinical Fellows, PhD Candidates or Early Stage Investigators for outstanding presentation of their abstracts. Awardees are selected on site and award recipients were announced during the last session on Sunday, June 11, 2017. These awards include a certificate and monetary award of $250.00 (US).

 

Cure HHT was honored to provide prizes for the best young scholar presentations. Congratulations to our winners!

Anthony Cannavicci, BSC, University of Toronto / St. Michael’s Hospital

Utility Of HHT Patient Specific Gene Mutations To Link Families In Databases

Daniel DePietro, MD, University of Pennsylvania

Can Graded Contrast Echocardiography Be Used For Post-Treatment Surveillance Of Pulmonary Arteriovenous Malformations?

Melissa Hector-Greene, PhD, Duke University

Role Of Type III Transforming Growth Factor-Β Receptor In Regulating ALK1 Signaling And Endothelial Biology

Anna Hosman, MD, PhD, St. Antonius Hospital

Age Related Sensitivity And Specificity Of The Curacao Criteria

Sara Plumitallo, PhD, University of Pavia

Circulating Micrornas In Hereditary Hemorrhagic Telangiectasia: Preliminary Results Identify Significant Differences Among Patients

Elisa Rossi, PhD, Université Paris Descartes

Human Endoglin As A Potential New Partner Involved In Platelet-Endothelium Interactions

Ali Tayebi-Meybodi, MD, University of California San Francisco

Surgical Treatment Versus Non-Surgical Treatment For Brain Arteriovenous Malformations In Patients With Hereditary Hemorrhagic Telangiectasia: A Retrospective Multicenter Consortium Study

Whitney Wooderchak-Donahue, PhD, University of Utah / ARUP Laboratory

Identification Of New Genes And Genetic Modifiers In HHT That Alter Clinical Severity

 

Up to eight awards will be given in these categories:

  • Best Clinical Oral Presentation
  • Best Scientific Oral Presentation
  • Best Clinical Poster Presentation
  • Best Scientific Poster Presentation